首页> 美国卫生研究院文献>PLoS Clinical Trials >Increased circulating microRNA-122 is a biomarker for discrimination and risk stratification in patients defined by sepsis-3 criteria
【2h】

Increased circulating microRNA-122 is a biomarker for discrimination and risk stratification in patients defined by sepsis-3 criteria

机译:循环microRNA-122的增加是脓毒症3标准所定义的患者歧视和危险分层的生物标志物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundSepsis is now operationally defined as life-threatening organ dysfunction caused by an infection, identified by an acute change in SOFA-Score of at least two points, including clinical chemistry such as creatinine or bilirubin concentrations. However, little knowledge exists about organ-specific microRNAs as potentially new biomarkers. Accordingly, we tested the hypotheses that micro-RNA-122, the foremost liver-related micro-RNA (miR), 1) discriminates between sepsis and infection, 2) is an early predictor for mortality, and 3) improves the prognostic value of the SOFA-score.
机译:背景技术现在,脓毒症在操作上被定义为由感染引起的威胁生命的器官功能障碍,可以通过SOFA-Score的急性变化至少两点来确定,包括临床化学,例如肌酐或胆红素浓度。然而,关于器官特异性microRNAs作为潜在的新生物标记物的知识很少。因此,我们测试了以下假设:micro-RNA-122,最重要的肝脏相关micro-RNA(miR),1)区分败血症和感染,2)是死亡率的早期预测指标,3)改善了预后的价值SOFA分数。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号